Merck Expands Vaccine Portfolio with FDA Approval of Capvaxive

Merck & Co., Inc. (NYSE:MRK) announced on June 18 that the U.S. Food and Drug Administration (FDA) granted an expanded approval for Capvaxive, as reported by TheFly. The approval extends the vaccine's indication to cover additional age groups or populations, strengthening Merck's position in the vaccine market.

The Product

Capvaxive is a pneumococcal vaccine designed to protect against multiple strains of Streptococcus pneumoniae bacteria. It offers broad coverage against the most common and virulent strains that cause serious diseases such as pneumonia and meningitis.

Pricing and Availability

Merck has not yet disclosed pricing details or the timeline for market availability. The company is expected to provide this information in upcoming official announcements.

Competition

Capvaxive faces competition from other pneumococcal vaccines, including Pfizer's Prevnar 20 and Merck's own Vaxneuvance. However, the expanded approval may provide a competitive edge by targeting populations not currently covered by existing vaccines.

Potential Impact on the Company

The new approval is expected to boost Merck's vaccine revenue, especially as demand for preventive vaccinations grows. It also supports the company's strategy to diversify its portfolio and reduce reliance on weight-loss drugs.